Literature DB >> 25963811

Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.

C A Alvarez1, I Lingvay2, V Vuylsteke3, R L Koffarnus3, D K McGuire2.   

Abstract

Cardiovascular disease is the principal complication and the leading cause of death for patients with diabetes (DM). The efficacy of antihyperglycemic treatments on cardiovascular disease risk remains uncertain. Cardiovascular risk factors are affected by antihyperglycemic medications, as are many intermediate markers of cardiovascular disease. Here we summarize the evidence assessing the cardiovascular effects of antihyperglycemic medications with regard to risk factors, intermediate markers of disease, and clinical outcomes.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25963811      PMCID: PMC4512912          DOI: 10.1002/cpt.143

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  75 in total

1.  Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus.

Authors:  Tsutomu Takagi; Atsushi Yamamuro; Koichi Tamita; Kenji Yamabe; Minako Katayama; Shigefumi Morioka; Takashi Akasaka; Kiyoshi Yoshida
Journal:  Am J Cardiol       Date:  2002-02-01       Impact factor: 2.778

2.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

Review 3.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Authors:  Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

Review 4.  Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms.

Authors:  Justin Saunders; Shiny Mathewkutty; Mark H Drazner; Darren K McGuire
Journal:  Herz       Date:  2008-04       Impact factor: 1.443

5.  Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

Authors:  M N Ghazzi; J E Perez; T K Antonucci; J H Driscoll; S M Huang; B W Faja; R W Whitcomb
Journal:  Diabetes       Date:  1997-03       Impact factor: 9.461

6.  Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.

Authors:  Shinji Ishikawa; Masayuki Shimano; Masato Watarai; Masayoshi Koyasu; Tomohiro Uchikawa; Hideki Ishii; Yasuya Inden; Kenji Takemoto; Toyoaki Murohara
Journal:  Am J Cardiol       Date:  2014-05-16       Impact factor: 2.778

7.  A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful.

Authors:  D S Schade; L Jovanovic; J Schneider
Journal:  J Clin Pharmacol       Date:  1998-07       Impact factor: 3.126

8.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

Review 9.  Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.

Authors:  Mohammad Katout; Hong Zhu; Jessica Rutsky; Parthy Shah; Robert D Brook; Jixin Zhong; Sanjay Rajagopalan
Journal:  Am J Hypertens       Date:  2013-11-21       Impact factor: 2.689

Review 10.  Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

Authors:  B Richter; E Bandeira-Echtler; K Bergerhoff; C L Lerch
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16
View more
  8 in total

1.  Effect of Irbesartan on AGEs-RAGE and MMPs systems in rat type 2 diabetes myocardial-fibrosis model.

Authors:  Ye Hongwei; Cao Ruiping; Fang Yingyan; Zhang Guanjun; Hu Jie; Liu Xingyu; Tang Jie; Li Zhenghong; Gao Qin; Hu Junfeng; Zhang Heng
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-26

2.  Antihyperglycemic and Antilipidemic Properties of a Tea Infusion of the Leaves from Annona cherimola Miller on Streptozocin-Induced Type 2 Diabetic Mice.

Authors:  Jesús Martínez-Solís; Fernando Calzada; Elizabeth Barbosa; Miguel Valdés
Journal:  Molecules       Date:  2021-04-21       Impact factor: 4.411

3.  Efficacy of negative pressure wound therapy using vacuum-assisted closure combined with photon therapy for management of diabetic foot ulcers.

Authors:  Xiaoxiao Hu; Weishuai Lian; Xiaojun Zhang; Xue Yang; Jinxia Jiang; Maoquan Li
Journal:  Ther Clin Risk Manag       Date:  2018-10-25       Impact factor: 2.423

4.  Effects of sodium-glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta-analysis of randomized controlled trials.

Authors:  Bingshu Wu; Hongzhi Zheng; Jianqiu Gu; Yan Guo; Yixuan Liu; Yingfang Wang; Feng Chen; Aolin Yang; Jiabei Wang; Hailong Wang; Ying Liu; Difei Wang
Journal:  J Diabetes Investig       Date:  2018-07-26       Impact factor: 4.232

5.  Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.

Authors:  Ya-Ru Wu; Xiao-Yun Shi; Chun-Yan Ma; Yue Zhang; Rui-Xia Xu; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2019-11-09       Impact factor: 9.951

Review 6.  Effect of Hesperidin on Cardiovascular Disease Risk Factors: The Role of Intestinal Microbiota on Hesperidin Bioavailability.

Authors:  Anna Mas-Capdevila; Joan Teichenne; Cristina Domenech-Coca; Antoni Caimari; Josep M Del Bas; Xavier Escoté; Anna Crescenti
Journal:  Nutrients       Date:  2020-05-20       Impact factor: 5.717

7.  Understanding the Activation of Platelets in Diabetes and Its Modulation by Allyl Methyl Sulfide, an Active Metabolite of Garlic.

Authors:  Navya Malladi; Ebin Johny; Shravan K Uppulapu; Vikas Tiwari; Md Jahangir Alam; Ramu Adela; Sanjay K Banerjee
Journal:  J Diabetes Res       Date:  2021-10-19       Impact factor: 4.011

Review 8.  Dietary Patterns and Cardiometabolic Outcomes in Diabetes: A Summary of Systematic Reviews and Meta-Analyses.

Authors:  Hana Kahleova; Jordi Salas-Salvadó; Dario Rahelić; Cyril Wc Kendall; Emilie Rembert; John L Sievenpiper
Journal:  Nutrients       Date:  2019-09-13       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.